- cafead Oct 12, 2020 at 10:12: AM
via Back in 2006, Novartis execs scooped up rights to Kyorin’s immunosuppressant drug program for KRP-203, an S1P drug that the pharma giant initially thought had some real potential.
But Mayzent (siponimod) ultimately stole the S1P show at Novartis, which would go on to win a first-in-class FDA OK in multiple sclerosis, with KRP-203 abandoned along the way still in early-stage development.
Until today.
article source
But Mayzent (siponimod) ultimately stole the S1P show at Novartis, which would go on to win a first-in-class FDA OK in multiple sclerosis, with KRP-203 abandoned along the way still in early-stage development.
Until today.
article source